Inclusion Criteria:

- Signed informed consent or thumb-printed and witnessed informed consent obtained
from the parent/legal guardian of the infant.

- Infants must have been born full-term (at ≥37 weeks of gestation) and > 2500 grams
at birth.

- Immunization schedule Cohorts 1, 2, and 3: : Male and female infants 42-49 days
(inclusive) of age at time of enrollment. For infants in Cohort 1, randomization to
receive vaccine dose 1 (Groups 1 and 2 of R21/MM or placebo, respectively) will
occur at 42-49 days of age. For infants in Cohort 2, randomization to receive
vaccine dose 1 (Groups 3 and 4 of R21/MM or placebo, respectively) will occur at 2
months (56-63 days of age). For infants in Cohort 3, randomization to receive
vaccine dose 1 (Groups 5 and 6 of R21/MM or placebo, respectively) will occur at 3
months (84-91 days of age).

- The participant's parent/guardian must be willing to avoid travel, particularly in
the 28 days after each study vaccination, must confirm willingness to contact the
study team in the event of unexpected/unavoidable travel and, for the safety cohort,
must confirm availability for the home visits to be conducted by a field worker to
collect solicited AEs over the 7 days (day of vaccination and 6 subsequent days)
following each study vaccine.

- The participant's parent/guardian must confirm willingness to bring their child to
the study clinic / local health care clinic, and capacity to contact the study team
in the event the subject has any illnesses or other health concerns during the
study.

- Participants who the investigator believes that their parent/guardian can and will
comply with the requirements of the protocol (e.g. return for follow-up visits) may
be enrolled in the study.

Exclusion Criteria:

- Acute disease at the time of enrolment (acute disease is defined as the presence of
a moderate or severe illness with or without fever. All vaccines can be administered
to participants with a minor illness such as diarrhea, mild upper respiratory
infection, without low-grade febrile illness, i.e. axillary temperature < 37.5°C).

- Clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine,
neurological, skin, hepatic or renal functional abnormality, as determined by
medical history, physical examination or laboratory tests which, in the opinion of
the Investigator, may either put the participants at risk because of participation
in the trial, or may influence the result of the trial.

- At time of enrollment, any infant who has received any dose of the
hexavalent/pentavalent vaccines, pneumococcal vaccine, rotavirus vaccine, IPV or has
received more than one dose of oral polio virus or more than one dose of hepatitis B
vaccine.

- Weight-for-height/length Z score of less than -3 or other clinical signs of
malnutrition.

- Infant with major congenital defects.

- The infant has anaemia associated with clinical signs of symptoms of decompensation,
or a haemoglobin of ≤ 5.0 g/dL.

- History of allergic disease or reactions likely to be exacerbated by any component
of the vaccines.

- Any confirmed or suspected immunosuppressive or immunodeficient state (including HIV
or asplenia) or known maternal HIV infection (no HIV testing will be routinely done
by the study team).

- Administration of immunoglobulins and/or any blood products/blood transfusion from
birth to time of planned administration of the vaccine candidate.

- Previous vaccination of participant or biological mother with a malaria vaccine.

- Participation in another research study involving receipt of an investigational
product or planned use during the study period.

- Any other findings that the investigator feels would increase the risk of having an
adverse outcome from participation in the trial.